Collectively, these results show that an intermediate dose of regorafenib with anti-PD1 blockade is required to promote vascular normalization, which reduces hypoxia and increases regorafenib delivery and activity in the HCC tissue. The gene discussed is PDCD1; the disease is hepatocellular carcinoma.